Rating and Price Target
Rating: Jefferies has maintained the rating for Bayer at “Hold”. This rating was assigned after the release of the latest figures.
Price Target: The price target for Bayer stock was set at 22 euros.
Business Segment Analysis
Pharmaceutical Business: Analyst Charlie Bentley praised Bayer’s well-performing pharmaceutical business. This segment has developed positively and contributes significantly to the adjusted operating corporate result.
Agricultural Division: The agricultural division has surpassed the lowered estimates, which is viewed positively. This shows that the agricultural chemistry sector remains defensive despite uncertain market conditions.
Over-the-Counter Medications: The over-the-counter medication business has fallen short of earnings expectations. This could be an area that continues to pose challenges.
Market Development and Investor Outlook
Market Development: The analysis may influence the market development for Bayer stock, as it provides investors with important information. A positive price reaction is expected based on the positive developments in the pharmaceutical business and agricultural division.
Investor Outlook: It is important for investors to monitor the various business segments of Bayer, as they exhibit different developments. The “Hold” rating could suggest that investors should maintain their positions rather than making new investments or selling their holdings.
Overall, Jefferies’ analysis offers a comprehensive assessment of Bayer stock, helping investors make informed decisions.